The platform has onboarded over 430,000 doctors, adding approximately 65,000 new users each month, and is currently used in over 8.5 million consultations monthly, demonstrating its widespread adoption and effectiveness.

The company's approach addresses critical healthcare challenges such as clinician burnout, doctor shortages, and the need for personalized care, creating a strong demand for AI decision-support tools.

OpenEvidence recently launched DeepConsult, an advanced AI feature that connects research findings and conducts in-depth analysis, significantly reducing the time physicians spend on literature review.

The platform's AI agents, part of DeepConsult, autonomously conduct research, streamlining the process for doctors and alleviating workload.

OpenEvidence's strategy includes partnerships with major medical journals and organizations like the American Medical Association and The New England Journal of Medicine, ensuring access to high-quality medical content.

OpenEvidence is a rapidly growing AI-driven healthcare platform, serving over 10,000 hospitals and medical centers across the United States, with more than 40% of U.S. physicians logging in daily to make critical clinical decisions.

Recently, OpenEvidence secured $210 million in Series B funding, which brought its valuation to $3.5 billion, with co-lead investors including Google Ventures and Kleiner Perkins.

Founder Daniel Nadler, who invested $10 million of his own money, now holds roughly 60% ownership, and his net worth has surged to an estimated $2.3 billion following the company's valuation.

Although not yet public, OpenEvidence's growth highlights a rising trend in AI-powered healthcare solutions, which could have significant implications for investors in the broader AI and healthtech sectors.

Investors such as Google Ventures, Coatue, Thrive Capital, and Kleiner Perkins are backing the company, with Kleiner Perkins' chairman comparing its potential impact in healthcare to Google's influence on the internet.

Market analysts suggest keeping an eye on upcoming pilot programs and regulatory developments, which will be key indicators of OpenEvidence's future trajectory.